# Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

> **NCT00781287** · PHASE4 · TERMINATED · sponsor: **University of Washington** · enrollment: 10 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** 3-drug anti-HIV therapy
- **DRUG:** Raltegravir

## Key facts

- **NCT ID:** NCT00781287
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2012-02
- **Final completion:** 2013-10
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Enrollment too slow.
- **Last updated:** 2013-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00781287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00781287, "Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00781287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*